Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus tirzepatide for body fat distribution and muscle-related metabolic markers in obesity
jRCT1061260079Recruiting
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial in obesity comparing Wegovy arm with Zepbound arm (2 arms). Primary endpoint: Change from baseline in visceral fat area. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT1061260079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260079.